Why the GSK share price should smash the FTSE 100 this year

Roland Head takes a look at FTSE 100 (INDEXFTSE:UKX) climber GlaxoSmithKline plc (LON:GSK) and highlights another turnaround opportunity.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Shares of pharma giant GlaxoSmithKline (LSE: GSK) have risen by 15% so far this year, outpacing a flat performance from the FTSE 100.

I first suggest this stock as a turnaround buy back in January and then again in March when news broke of the group’s decision to buy out Novartis from the pair’s consumer healthcare joint venture for $13bn.

At that time the stock was trading on around 12 times 2018 forecast earnings and offering a 6% yield. The group’s rising share price has upped this price tag. Glaxo shares now trade on 14 times 2018 forecast earnings, with a 5.3% yield.

For comparison, the FTSE 100 currently trades on a P/E of 13.5 with a dividend yield of 3.8%. So Glaxo looks still reasonably priced compared to the index. And the group may also have some tricks up its sleeve.

Staying together could be profitable

A number of prominent investors including Neil Woodford have called for the group to break itself up into two or three smaller and more focused businesses. I have some sympathy with this view, but it seems that chief executive Emma Walmsley isn’t keen.

Ms Walmsley appears determined to keep the group together and improve its performance by bulking up in key areas of strength. The acquisition of the remaining share of the Consumer Healthcare joint venture is an example of this.

This decision isn’t without risk. Much of the $13bn recently paid to Novartis for its share of the consumer healthcare business was funded with debt. But the operating margin from selling products such as Panadol and Sensodyne is expected to rise from 17.7% in 2017 to “mid-20s percentages” by 2022.

I estimate that achieving this alone could add about £550m to Glaxo’s 2017 operating profit of £4.1bn, even before any sales growth is considered.

I still see value

At Glaxo’s current valuation, I believe the shares still offer decent value for long-term income investors. Although this group has underperformed the market over the last five years, profits seem to have stabilised and free cash flow is improving. This should support both the dividend and some level of debt reduction.

For income investors, I believe Glaxo’s 5.3% yield represents a decent buy.

This 6% yielder could motor ahead

Public transport operators are not exactly the flavour of the month at the moment. Many rail commuters will know why. But my pick from this sector, FTSE 250 firm Go-Ahead Group (LSE: GOG), looks like a potential value buy to me.

As with Glaxo, Go-Ahead’s share price has motored ahead this year. The stock is now worth about 10% more than at the start of January.

What’s changed?

The group’s troubled Southern Rail franchise has gathered a lot of headlines. But the reality is that the financial results of the rail division were ahead of expectations during the six months to 31 December. The group’s bus operations are also performing well and a number of new overseas contracts are in the pipeline.

Revenue rose by 6.6% to £1,829.4m during the half-year, while operating profit climbed 19% to £86.9m. The group’s third-quarter trading statement shows that this performance has continued, with profit guidance left unchanged for buses and upgraded for rail.

A cash machine

The company seems to be leaving last year’s problems behind. And its financial performance is improving. Cash generation has always been a core attraction here and this is starting to recover, after a difficult period in 2016/17.

I estimate that Go-Ahead’s forecast dividend of 102p per share should be covered by free cash flow this year. With a 2017/18 price/earnings ratio of 8.9 and a forecast dividend yield of 6.1%, this stock is on my buy list at the moment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

With a spare £500 I’d buy these UK shares

A financial services giant, a FTSE 250 distributor, a FTSE 100 tech stock, and a gold miner are on the…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Should I buy this defensive FTSE 100 stock for growth and returns?

This Fool takes a closer look at a FTSE 100 stock to see if it could boost his holdings via…

Read more »

Young female analyst working at her desk in the office
Investing Articles

I robbed Mr Market of this cheap FTSE stock!

This FTSE 250 stock has crashed by almost 30% in six months. But I recently bought into this battered business…

Read more »

Mature people enjoying time together during road trip
Investing Articles

3 reasons I’m backing NIO shares to soar!

NIO shares have bounced up and down this year. But where will the share price go next? My bet is…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Up 300%, is the Hurricane Energy share price an opportunity too good to miss?

This Fool looks at why the Hurricane Energy share price has soared in the past 12 months. Should he buy…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

The BT share price crashes 20% in a month. Buy now?

The BT share price has crashed by almost a fifth since coming close to £2 on 12 July. After this…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

How I’d invest £1,000 in growth shares today to target £5,000 in a decade

Our writer reckons he could do well by choosing the right growth shares today and holding them in his portfolio…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

How passive income from stocks can speed up early retirement

By investing patiently over the years, buying quality shares has given me enough passive income to retire 10 or even…

Read more »